

Leadership



Ph.D, Dalia El-Ani **Founder, CEO and Chief Scientist**

Has more than 25 years experience leading research projects in cardiovascular and neuronal science.



Ph.D, David Kain **Director of animal experiments**

Expert in animal models and imaging .
Cardio scientific consultant at Weizmann Institute of Science.



Ph.D, Raziel Hamami **Director of stem cells and Tissue engineering experiments**

Experienced in tissue engineering, computational biology methods ,
cell cultures, cell therapy and encapsulation.



Reuven Ulmansky **Business Development VP**

Well-known business leader in the Israeli entrepreneurial ecosystem ,
serving as a strategic and business advisor.

Advisory Board



Dr. Moshe Neuman **Regulatory Advisor**

Founder and Managing Director of Bio Medical Research Design Ltd. (B.R.D), a leading Israeli regulatory affairs consulting Firm, providing professional expert advice and integrated services to Israeli startup companies.



Dr. Ronald Ellis **Business Consulter**

Principal Consultant at Biotech & Biopharma Consulting.
Leading R&D for biologics, immunotherapeutics and vaccines.




Prof. Reuven Zimlichman, M.D **Senior Cardiologist**

Director of the Institute for Quality in Medicine, Israeli Medical Association & Director of Cardiovascular Research Institute, Sackler Faculty of Medicine.


The Market



Acute heart failure treatments



The global CRISPR technology market



10M Death/year in the World

Business Model



Crispr Stem Therapeutics

- Protocol Patent
- Service
- Training
- Guidance



Pharmaceutical Company

- Manufacture
- Marketing
- Distribution
- Sells


According to
the manufacturer
strategy



Target Market

- Hospitals
- Insurance companies
- Private clients

Development Roadmap



*Patent entered national phase

Major Achievements



Received 2 seals of excellence
in sciences from the European
Union Commission

A few months ago our patent
was accepted In U.S and China
and entered into the national
phase in Europe.

Received funding from the
Israel Innovation Authority

Tested technology in several
proof of concept experiments

Our product dramatically
decreased heart attack
damages and have promising
cardio protective effect

Investment Goals



\$5000,000

Two years of activity

- Personnel recruitment
- Pre-clinical Trials
- Legislation and regulation



Thank You!

<http://www.crisprstemtherapeutics.com/>

[E-mail: Daliae@crisprstemtherapeutics.com](mailto:Daliae@crisprstemtherapeutics.com)

Dr.Elani.Dalia@gmail.com